Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 Among Previously Infected Healthcare Personnel and First Responders중증급성호흡기증후군 코로나바이러스 2로 이전에 감염된 의료진과 응급구조원 중 재감염Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus adjusted hazard ratio antibody association circulation coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 defined exposure to first positive first responders hazard healthcare healthcare personnel household transmission Lower MOST New York City nursing home occurred participant Participants participated positive proportional hazards model Protective provided reduced Reinfection respiratory Responder Rhode Island risk SARS-CoV-2 SARS-CoV-2 test serology test seronegative seropositive seropositive participant seropositive participants Seropositivity serostatus Serosurvey severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Spike protein tested variant virus virus test widespread with COVID-19 [DOI] 10.1093/cid/ciab952 PMC 바로가기 [Article Type] Article
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load코로나19 고위험 보행 환자를 대상으로 한 밤라니비맙과 에테세비맙의 무작위 위약 대조 임상 시험 및 지속적으로 높은 바이러스 부하의 예후 가치 검증Randomized Controlled Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 임상, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age ambulatory ambulatory patient ambulatory patients antibody treatment applicability bamlanivimab baseline characterized clinical clinical status Cohort confidence interval coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 test Day death determine etesevimab expand first positive greater high risk Hospitalization infused Interim analyses interim analysis intravenously investigated load lower dose median median age Mild-to-moderate NCT04427501 occurred optimal dose outcome Patient persistently high viral load. phase Placebo placebo group receiving reduction in respiratory risk factor SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe COVID-19 Support the placebo group These data those receiving placebo Treatment Trial validation value variant Viral Viral load [DOI] 10.1093/cid/ciab912 PMC 바로가기 [Article Type] Randomized Controlled Trial
Interferon α-2b spray shortened viral shedding time of SARS-CoV-2 Omicron variant: An open prospective cohort study인터페론 α-2b 스프레이는 SARS-CoV-2 오미크론 변이체의 바이러스 배출 시간을 단축: 공개 전향 코호트 연구Article Published on 2022-08-052022-09-11 Journal: Frontiers in Immunology [Category] SARS, 변종, 치료제, [키워드] 95% CI administration adverse effect against SARS-CoV Analysis antiviral activity China Cohort cohort study control group COVID-19 Effect Effectiveness enrolled examined experimental group first positive IFN IFN α IFN α-2b spray interferon less omicron Omicron variant participant Patient prospective cohort study protective effect protective factor SARS-CoV-2 SARS-CoV-2 Omicron variant SARS-CoV-2 variant Shanghai shown significantly spray Spread subgroup analysis the median treatment effect treatment effects univariate Cox regression univariate Cox regression analysis Vaccine viral shedding viral shedding time virus clearance virus transmission [DOI] 10.3389/fimmu.2022.967716 PMC 바로가기 [Article Type] Article
“Bring the Hoses to Where the Fire Is!”: Differential Impacts of Marginalization and Socioeconomic Status on COVID-19 Case Counts and Healthcare CostsResearch article Published on 2022-08-012022-10-05 Journal: Value in health : the journal of the International [Category] 진단, [키워드] acute respiratory syndrome age analysis of variance Canada Care Community Comorbidity Concentration controls coronavirus costs and costs analyses count COVID-19 COVID-19 case database Deprivation Diagnosis dimension examined female females fire first positive Health healthcare highest highlight Hose Hospitalized Impact IMPROVE individual Infection intensive care male marginalization measure MOST objective outcomes reduce reducing remained resource Result retrospective cohort study risk of COVID-19 Sex skewed socioeconomic status status universal healthcare were assessed World Health Organization [DOI] 10.1016/j.jval.2022.03.019 [Article Type] Research article
Global influenza surveillance systems to detect the spread of influenza-negative influenza-like illness during the COVID-19 pandemic: Time series outlier analyses from 2015-2020COVID-19 전염병 동안 인플루엔자 음성 인플루엔자 유사 질병의 확산을 감지하기 위한 글로벌 인플루엔자 감시 시스템: 2015-2020년의 시계열 이상치 분석Article Published on 2022-07-192022-09-11 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 치료기술, [키워드] Analysis analyzed ARIMA automated average baseline changes in Completeness country COVID-19 COVID-19 case COVID-19 pandemic data-driven detect disease emerging disease evaluate exceeded first positive Health Organization highest identify ILI Influenza interpolation limitation linear linear interpolation Missing data moving average National observation occurred Outbreaks outlier outliers pathogen performed Poland positive primary analysis reported response SARS-CoV-2 SARS-CoV-2 positivity sensitivity analysis Spain Spread spread of COVID-19 Standard deviation Surveillance surveillance data surveillance network System time training data used data World Health Organization [DOI] 10.1371/journal.pmed.1004035 PMC 바로가기 [Article Type] Article
Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failureShort communication Published on 2022-07-012022-10-05 Journal: Vaccine [Category] COVID19(2023년), SARS, 바이오마커, 임상, [키워드] age Aged breakthrough infections Characteristics clinical Clinical characteristics Comorbidity COVID COVID-19 COVID-19 breakthrough infections COVID-19 vaccine COVID-19 vaccines death described Elderly patient first positive Hospitalization Hospitalized immunization IMPROVE low-flow oxygen therapy male Mortality Older Older age outcome overall mortality Patient Prognosis SARS-CoV-2 PCR significantly specific treatment treatment with tocilizumab vaccination Vaccine with COVID-19 [DOI] 10.1016/j.vaccine.2022.06.003 [Article Type] Short communication
The latent period of coronavirus disease 2019 with SARS-CoV-2 B.1.617.2 Delta variant of concern in the postvaccination era2019년 SARS-CoV-2 B.1.617.2 예방 접종 후 시대 우려 델타 변종 코로나바이러스 질병 잠복기Article Published on 2022-07-012022-09-11 Journal: Immunity, Inflammation and Disease [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 B.1.617.2 Clinical data collected comparable coronavirus coronavirus disease COVID-19 Date delta variant Delta VOC distribution Epidemic Epidemiology female patient Female patients first positive Infection interquartile range latent period male median median age not significantly different Patient patients PCR test postvaccination Prevent Prevention and control quarantine retrospective SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 the SARS-CoV-2 Transmission Vaccine variant variant of concern VoC [DOI] 10.1002/iid3.664 PMC 바로가기 [Article Type] Article
Case Report: Successful Treatment With Monoclonal Antibodies in One APDS Patient With Prolonged SARS-CoV-2 Infection Not Responsive to Previous Lines of Treatment증례 보고: SARS-CoV-2 감염이 오래 지속된 APDS 환자 1명에서 단일클론항체로 성공적인 치료Case Reports Published on 2022-06-212022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] activated activated PI3K delta syndrome (APDS) administration affected APDS clearance COVID19 described Efficacy first positive genotyping IEI Infection LINE long-lasting long-lasting infection monoclonal monoclonal antibodies monoclonal antibody multiple therapeutic agent multiple therapeutic agents neutralizing monoclonal antibodies other treatments Patient pauci-symptomatic PI3K Prolonged reducing Remdesivir SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 virus Swab syndrome tested the SARS-CoV-2 virus therapeutic agents Tolerability treated Viral viral shedding virus wild type [DOI] 10.3389/fimmu.2022.891274 PMC 바로가기 [Article Type] Case Reports
Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study델타 변이체(B.1.617.2) 및 스코틀랜드 환자의 2차 접종 이후 경과 시간(REACT-SCOT)과 관련된 중증 COVID-19에 대한 백신 효능: 사례-대조군 연구Article Published on 2022-06-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, [키워드] 95% CI age Alpha Analysis ascertainment bias B.1.1.7 B.1.617.2 booster doses Case-control case-control study ChAdOx1 ChAdOx1 vaccine classification coded community health Control controls COVID-19 Critical care database death declined decrease defined delta variant diagnosed dose Efficacy expected first positive Follow-up hospitalisation include index measure Moderna mRNA mRNA vaccine mRNA vaccines not limited outcome Patient Pfizer predominant presenting primary care primary outcome measure Protective replaced replacement report reported reversed risk SARS-CoV-2 variant Scottish second dose selected Severe case severe cases severe COVID-19 severe disease severity Sex study period suggested Support transmission rate transmission rates vaccination Vaccine vaccine efficacy Vaccines variant [DOI] 10.1016/S2213-2600(22)00045-5 PMC 바로가기 [Article Type] Article
Drugs used during the COVID-19 first wave in Vitoria-Gasteiz (Spain) and their presence in the environmentVitoria-Gasteiz(스페인)의 COVID-19 1차 물결 동안 사용된 약물과 환경에서의 존재Article Published on 2022-05-102022-09-11 Journal: The Science of the total environment [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] Administered affected Analysis Antiviral antiviral activity Azithromycin benefit cisatracurium city Concentration country COVID 19 COVID-19 COVID-19 pandemic defined detrimental effects dose drug Drug pollution first positive First wave healthcare professionals hospital Hydroxychloroquine ICUs intensive care unit intensive care units lAbel LC-q-Orbitrap Lopinavir LOPINAVIR AND RITONAVIR Lopinavir/ritonavir medium one health pandemic Patient patients pharmacoepidemiology positive potential risk proportion Quotient risk Ritonavir SARS-CoV2 selected drug selected drugs situation Spain target Target analysis. Treatment urgency Vitoria were used [DOI] 10.1016/j.scitotenv.2022.153122 PMC 바로가기 [Article Type] Article